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Objectives This study sought to estimate lifetime risk for heart failure (HF) by sex and race.
Background Prior estimates of lifetime risk for developing HF range from 20% to 33% in predominantly white cohorts. Short-
term risks for HF appear higher for blacks than whites, but only limited comparisons of lifetime risk for HF have
been made.
Methods Using public-release and internal datasets from National Heart, Lung, and Blood Institute–sponsored cohorts, we
estimated lifetime risks for developing HF to age 95 years, with death free of HF as the competing event, among
participants in the CHA (Chicago Heart Association Detection Project in Industry), ARIC (Atherosclerosis Risk in
Communities), and CHS (Cardiovascular Health Study) cohorts.
Results There were 39,578 participants (33,652 [85%] white; 5,926 [15%] black) followed for 716,976 person-years;
5,983 participants developed HF. At age 45 years, lifetime risks for HF through age 95 years in CHA and CHS
were 30% to 42% in white men, 20% to 29% in black men, 32% to 39% in white women, and 24% to 46% in
black women. Results for ARIC demonstrated similar lifetime risks for HF in blacks and whites through age 75
years (limit of follow-up). Lifetime risk for HF was higher with higher blood pressure and body mass index at all
ages in both blacks and whites, and did not diminish substantially with advancing index age.
Conclusions These are among the first data to compare lifetime risks for HF between blacks and whites. Lifetime risks for HF
are high and appear similar for black and white women, yet are somewhat lower for black compared with
white men due to competing risks. (J Am Coll Cardiol 2013;61:1510–7) © 2013 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.022Heart failure (HF) is a growing public health crisis, with
increasing morbidity, mortality, and costs (1). Declines in
HF incidence over previous decades have flattened, with
increases in HF prevalence due to lower case-fatality rates
(2,3). Indeed, HF prevalence increased by as much as 30%
in Medicare beneficiaries from 1994 to 2003 (4). This
increased prevalence of HF, however, may not be solely a
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April 9, 2013:1510–7 Lifetime Risk for Heart Failure by Sex and RaceRotterdam studies (10), 2 cohorts of almost exclusively white
individuals of European ancestry. However, these studies used
different criteria to define HF (11,12), which may partially
account for the differences in lifetime risk.
Whereas short-term risks for HF incidence appear to be
significantly higher for blacks than whites in the United
States (13,14), only limited comparisons of lifetime risk for
HF have been made between white and black individuals
(15). Lifetime risk estimates account for the risk of incident
HF as well as for the risk of death from competing causes,
and overall and noncardiovascular mortality risk is known to
be higher among blacks than whites (especially in men).
Therefore, it is unknown whether lifetime risks for HF
differ between blacks and whites. Further, knowledge of
absolute lifetime risk estimates may be useful for policymak-
ers, patients, and physicians alike to estimate the current
and future population burden of disease, as well as to
estimate individual risks. A similar strategy used for breast
cancer risk estimation has been cited as a contributor to
increased breast cancer screening in the 1990s (16,17).
We sought to define and compare the lifetime risks for
HF by sex and race at selected ages in several diverse
population samples by examining the results of prospec-
tive, observational studies with data on HF endpoints,
namely CHA (the Chicago Heart Association Detection
Project in Industry) (18), ARIC (Atherosclerosis Risk In
Communities Study) (19), and CHS (Cardiovascular
Health Study) (20).
Methods
Cohorts. This analysis was undertaken as part of the
ardiovascular Lifetime Risk Pooling Project (21). Using
ublic-release and internal datasets from National Heart,
ung, and Blood Institute–sponsored cohorts, namely
HA (internal dataset), ARIC (public-release dataset), and
HS (internal dataset), we estimated lifetime risk for
eveloping overt HF.
The CHA study examined 37,572 participants in Chi-
ago, Illinois, between the ages of 18 and 74 years (43%
omen, 10% black) from 1967 to 1973 (18). CHA partic-
pants were followed through 2003. Incident HF was
efined by Medicare hospital discharge coding in the CHA
ohort (International Classification of Diseases 9th Revision
ICD-9] codes 428.*, primary discharge diagnosis only).
ecause data were derived from Medicare hospitalization
ata, only HF hospitalizations from Medicare-eligible par-
icipants were captured beginning in 1984, the first year
edicare data were available for public use, through 2003.
ollow-up for vital status was completed by direct mail,
elephone, contact with employer, and matching of records
ith Social Security Administration files before 1979; from
979 to 1994, follow-up was completed through the Na-
ional Death Index (13). Death certificates were obtained
nd coded for multiple causes by trained research staff
ccording to the Eighth Revision of the International Classifica-tion of Diseases (ICD-8) (22).
From 1995 to 1998, the National
Death Index-plus service was used
to obtain ICD Ninth Revision
(ICD-9) cause of death coding and
ICD Tenth Revision (ICD-10)
coding from 1999 to 2003 (14,23).
For this report, the underlying cause
of death was used. HF mortality was
defined as ICD-8 and ICD-9 code
428 and ICD-10 codes I50.1 to
I50.4.
The ARIC study enrolled
15,721 participants ages 45 to 64 years at 4 sites (Min-
neapolis, Minnesota; Jackson, Mississippi; Forsyth
County, North Carolina; Washington County, Mary-
land; 55% women, 27% black) from 1987 to 1989 (19).
ARIC participants were followed through 2005. Individ-
uals with prevalent HF were excluded using the Gothen-
burg criteria. Incident HF cases were ascertained by
annual interviews of ARIC participants and review of
local hospital discharge logs to find HF hospitalizations
and by review of health department death certificates to
find HF deaths. Incident HF was defined by Medicare
hospital discharge coding for the ARIC cohort (ICD-9
codes 428.*, primary discharge diagnosis only) for hospi-
talization or by death certificate (ICD-9 codes 428.*;
ICD-10 codes I50.*). Incident HF cases were adjudicated
by a central committee of physician reviewers, as previ-
ously described (13).
The CHS, a cohort of Medicare-eligible older Ameri-
cans, enrolled 5,888 participants 65 years from 4 sites
(Sacramento County, California; Allegheny County, Penn-
sylvania; Forsyth County, North Carolina; Washington
County, Maryland; 58% women, 16% black) from 1989 to
1993 (20). CHS participants were followed through 2004.
In this cohort, incident HF was defined by a central
adjudication committee that relied upon results from semi-
annual contacts with participants and Medicare hospital
discharge data (ICD-9 codes 428.*, primary discharge
diagnosis only). HF events were confirmed by physician
review of identifying clinical evidence such as physician
diagnosis, physical or x-ray findings, or drug treatment with
diuretics, digitalis, or vasodilators. The causes of death were
adjudicated by the same endpoint central adjudication
committee (20).
Statistical analysis. All statistical analyses were per-
formed using SAS statistical software (version 9.1, SAS
Institute, Cary, North Carolina). Lifetime risks were
estimated using a modified life-table analysis using the
Practical Incidence Estimator macro, in which each
participant contributes information for each age attained
during follow-up, as previously described (24). For the
calculation of lifetime risks, a modified Kaplan-Meier
method was used that accounts for competing risk from
Abbreviations
and Acronyms
BMI  body mass index
BP  blood pressure
CI  confidence interval
CVD  cardiovascular
disease
HF  heart failure
ICD  International
Classification of Diseases
MI  myocardial infarctiondeath free of HF to avoid lifetime risk overestimation. In
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free of HF as a competing risk rather than a withdrawal
(as in the traditional Kaplan-Meier analysis) at the time
of event (see the Online Appendix for additional details).
All participants free from HF at selected index ages (45,
55, 65, and 75 years) were included. We estimated
lifetime risk for HF to age 95 years, with death free of
HF as the competing event, as described in the previous
text. In order to demonstrate the difference between
unadjusted Kaplan-Meier and adjusted lifetime risk esti-
mates, we created cumulative risk curves using the same
data. The difference between these curves represents the
competing risks of death from causes other than HF.
Participants were also stratified by body mass index
(BMI) into 3 groups (BMI 25, 25 to 29, and 30 kg/m2)
based on height and weight measured within 2 years of the
index age in order to evaluate the association between
obesity and lifetime risk for HF. We limited these analyses
to a follow-up time of 30 years due to smaller sample sizes.
In order to investigate the association between blood
pressure (BP) and lifetime risk for HF, we stratified partic-
ipants by BP level as measured within 2 years of each index
age. Again, we limited follow-up time to 30 years due to
sample size. The BP strata included: 120/80 mm Hg;
121 to 139 mm Hg (systolic) or 81 to 89 mm Hg (diastolic);
140 to 159 mm Hg (systolic) or 90 to 99 mm Hg (diastolic);
and 160 mm Hg (systolic), 100 mm Hg (diastolic), or
treated hypertension. Participants with treated hypertension
were included in this final stratum due to the overall small
size of this group, which was not adequately powered to
address lifetime risks. It was also not known whether such
treated participants were treated to an optimal BP target
throughout each study. Inclusion of the treated participants
would conservatively underestimate the lifetime risk for HF
in this highest BP stratum.
Finally, we performed analyses to examine the remaining
lifetime risk for HF attributable to causes other than MI. In
this analysis, we excluded participants with a history of
recognized or unrecognized MI before or at the index
examination and only considered those who developed HF
without an intervening MI during follow-up.
Informed consent. All cohorts included here have been
approved by the institutional review board from each
contributing institution, including Northwestern Univer-
sity. Participants provided informed consent at each
examination.
Results
Baseline characteristics for included participants in the
CHA, ARIC, and CHS cohorts are shown in Table 1. After
the index age of 45 years, CHA participants developed
3,972 HF events over 501,127 person-years of follow-up
(7.9 per 1,000 person-years); after age 45, ARIC partici-
pants developed 1,010 HF events over 168,516 person-years
of follow-up (6.0 per 1,000 person-years); and after the iindex age of 65 years, CHS participants developed 1,001
HF events over 47,333 person-years of follow-up (21.1 per
1,000 person-years).
In the CHA cohort, the remaining lifetime risks for HF at
age 45 through 95 years were 30.2% (95% confidence interval
[CI]: 28.9% to 31.5%) for white men, 20.1% (15.8% to 24.4%)
for black men (through 90 years), 32.3% (30.8% to 33.8%) for
white women, and 23.7% (17.8% to 29.8%) for black women
(through 90 years) (Figs. 1A and 1B). The overlap of these
estimates in women through index ages 75 years and 85 years
indicates that lifetime risks for HF were similar between black
and white women, whereas lifetime risks for HF were generally
lower among black men than white men in CHA. With
advancing index ages, lifetime risks for HF did not decrease,
despite an increase in the competing risk of HF-free death in
all groups. For example, the lifetime risks for HF in white men
in CHA at ages 45 and 55 years were 30.2% (95% CI: 28.9%
to 31.5%) and 28.5% (27.1% to 29.9%), respectively.
In the ARIC cohort, the remaining lifetime risk for HF
through age 75 years, which was near the limit of follow-up, was
19.1% (17.0% to 21.2%) for white men and 21.3% (17.5% to
25.1%) for black men (Fig. 1A). In women, the lifetime risk for
HF through age 75 was 13.4% (11.3% to 15.4%) in white women
compared with 23.9% (20.1% to 27.6%) in black women
(Fig. 1B). At the index ages of 45 and 55 years, remaining
lifetime risks for HF through age 75, the limit of
follow-up in the ARIC cohort, appeared higher for
whites and blacks in ARIC compared with whites and
blacks in CHA.
In the CHS cohort, the remaining lifetime risk for HF at
age 65 through 95 years was 41.6% (38.0% to 45.1%) for
white men and 29.1% (21.1% to 37.1%) for black men (Fig. 1C).
Remaining lifetime risks for HF were 38.5% (35.2% to
41.9%) for white women and 46.1% (38.0% to 54.1%) for
black women (Fig. 1D). As seen in the CHA cohort, the
lifetime risk for HF in CHS participants also did not
substantially decrease with advancing index age.
Lifetime risks for HF by BMI strata. When we stratified
participants by BMI, lower BMI strata were associated
with lower adjusted cumulative risks for HF in all
sex–race groups through age 75 years. Table 2 demon-
strates that remaining lifetime risk for HF tended to
increase with higher BMI at all index ages for all sex and
race groups. For example, lifetime risk for HF among
black women at index age of 45 years ranged from 4.4%
(0.2% to 8.6%) in women with BMI 25 kg/m2, to
1.8% (7.5% to 36.1%) in women with BMI 30 kg/m2.
imilar trends were also seen in the ARIC and CHS
ohorts (data not shown).
ifetime risks for HF by BP strata. When participants
ere stratified by BP level, lower lifetime risks were seen in
articipants with optimal BP compared with higher lifetime
isks with stage II/treated hypertension. Table 3 demon-
trates that remaining cumulative risk for HF, adjusted for
he competing risk of death through age 75 years, tended to
ncrease with higher BP for all sex and race groups in CHA
diast
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tive risks in white men ranged from 9.8% (5.6% to 13.9%)
with BP 120/80 mm Hg, to 16.3% (13.5% to 19.2%)
with systolic BP 160 mm Hg, diastolic BP 100 mm Hg
or treated hypertension. A similar pattern of results was
observed at all index ages for all sex–race groups in CHA
and the other cohorts (data not shown).
Lifetime risks for HF in the absence of antecedent
MI. We performed sex-specific- and race-specific esti-
mates of lifetime risk for HF after accounting for the
competing risk of antecedent MI (Table 4). Lifetime risks
were lower in participants without prior MI in nearly all
sex–race groups but remained high, ranging from 18.6%
(14.4% to 22.9%) in black men, to 28.7% (27.3% to 30.2%)
in white women at an index age of 45 years in CHA and
from 22.1% (15.0% to 29.2%) in black men, to 36.3%
Baseline Characteristics of Participants FreeFrom HF From th CHA, ARIC, and CHS Cohorts
Table 1 B seline Characteristics of ParticipFrom HF From the CHA, ARIC, and
CHA (N  1
Index age, yrs 45
Follow-up, person-years 501,127
Total HF events 3,972
White men 10,017 (5
SBP, mm Hg 142.9 2
DBP, mm Hg 84.3 1
BMI, kg/m2 27.2 3
BP medication, % 6
History of diabetes, % 4
History of myocardial infarction, % 2
Black men 545 (2
SBP, mm Hg 146.3 2
DBP, mm Hg 87.9 1
BMI, kg/m2 27.3 4
BP medication, % 6
History of diabetes, % 3
History of myocardial infarction, % 1
White women 8,379 (4
SBP, mm Hg 138.3 2
DBP, mm Hg 80.7 1
BMI, kg/m2 25.2 1
BP medication, % 9
History of diabetes, % 2
History of myocardial infarction, % 2
Black women 450 (2.
SBP, mm Hg 140.1 2
DBP, mm Hg 84.3 1
BMI, kg/m2 26.5 4
BP medication, % 13
History of diabetes, % 3
History of myocardial infarction, % 0
Values are n, n (%), and median  SD. Sample sizes are lower than
collected only at prespecified index ages of 45 and 65 years.
ARIC  Atherosclerosis Risk in Communities; BMI  body mass
in Industry Project; CHS  Cardiovascular Health Study; DBP 
pressure.(28.8% to 43.8%) in black women at an index age of 65 yearsin CHS. Similar trends were seen for ARIC, despite the
limited follow-up to age 75 years.
Unadjusted risk for HF compared with lifetime risk.
Figures 2A (men) and 2B (women) compare unadjusted
risks for HF (Kaplan-Meier cumulative incidence) with the
lifetime risks for HF in the CHA cohort at the index age of
45 years. Because the unadjusted Kaplan-Meier cumulative
incidence does not account for the risk of HF-free death,
the competing event, the Kaplan-Meier estimates for cu-
mulative incidence of HF are substantially higher than the
adjusted cumulative lifetime risks. The differences between
the unadjusted and adjusted cumulative incidence curves
represent the burden of competing risk from death free of
HF. For example, the unadjusted risk of noncardiovascular
disease (non-CVD) death rates in the CHA cohort are
shown in Figure 2 separately for black and white men and
Free
Cohorts
ARIC (N  15,732) CHS (N  4,455)
45 65
168,516 47,333
1,010 1,001
5,426 (34.5) 1,492 (33.5)
120.1 16.1 136.1 21.1
73.2 9.8 72.3 11.3
27.4 4.0 26.4 3.6
20.3 34.5
7.8 8.0
1.8 9.5
1,629 (10.4) 248 (5.6)
130.5 21.9 138.1 20.9
82.5 13.0 76.6 11.6
27.6 4.9 26.7 3.9
34.4 44.8
16.2 11.4
1.9 4.4
6,050 (38.5) 2,288 (51.0)
117.0 17.6 135.1 21.1
69.5 9.8 69.2 10.8
26.6 5.5 26.2 4.9
19.5 37.7
6.6 6.5
0.8 4.7
2,627 (16.7) 427 (9.6)
128.2 21.5 143.1 23.3
78.2 11.7 74.7 11.1
30.8 6.5 29.4 5.9
44.6 62.3
18.7 9.0
1.3 4.2
ample sizes for these cohorts because these measures reflect data
BP  blood pressure; CHA  Chicago Heart Association Detection
olic blood pressure; HF  heart failure; SBP  systolic bloodants
CHS
9,391)
1.7)
0.3
1.7
.6
.8
.1
.7
.8)
4.1
4.3
.2
.3
.7
.3
3.2)
0.8
1.5
.4
.3
.6
.2
3)
4.4
4.4
.9
.3
.9
.9
total s
index;women at an index age of 45 years (25). After 20 years of
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Lifetime Risk for Heart Failure by Sex and Race April 9, 2013:1510–7follow-up, the incidence of non-CVD death in black men
was 11.8%, compared with 7.6% in white men. Therefore,
the greater burden of non-CVD mortality among black men
particularly appears to limit lifetime risks for HF in this
group.
Discussion
These are among the first data to explore the lifetime risk
for HF in different race/ethnic groups. Overall, remaining
lifetime risks for HF are high (20% to 45%) in all groups,
and appear similar for black and white women and some-
what lower for black men compared with white men.
Figure 1 Lifetime Risks for HF in White and Black Americans
Lifetime risks (LR) for heart failure (HF) at an index age of 45 years for black and
Project (CHA) and Atherosclerosis Risk in Communities (ARIC) cohorts and LR for h
the Cardiovascular Health Study (CHS).Despite differences in birth cohort, age, and diagnosticcriteria, we find remarkably similar results between blacks
and whites. Risk factors for increasing lifetime risks for HF
in whites—such as obesity, BP, and nonfatal MI—appear to
increase the lifetime risks for HF in blacks in a similar
fashion. The rising obesity prevalence in the United States
makes this consistent association particularly relevant to the
future HF risk. Also, lifetime risk for HF did not diminish
with advancing age, because it is more common in older
individuals, despite the increased risk of HF-free death, and
hence, the shorter remaining lifespan during which HF can
occur.
The unadjusted risk for HF in black men was highest
men (A) and women (B) in the Chicago Heart Association Detection in Industry
ailure at an index age of 65 years for black and white men (C) and women (D) inwhite
eart famong all sex–race groups, as has been described in a
justed
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April 9, 2013:1510–7 Lifetime Risk for Heart Failure by Sex and Racepopulation of younger adults (26). However, the lower
lifetime risks for HF appear to be a product of higher
overall risks for HF among African Americans that were
counterbalanced by greater competing risks for death
from noncardiovascular causes, particularly among
African-American men, due to causes such as homicide,
renal failure, and HIV (27).
The lifetime risks for developing HF in the present
cohorts are higher than previously reported in the Framing-
ham and Rotterdam cohorts. These differences may be
related, in part, to how incident HF was defined in each
cohort. The Framingham Heart Study, in which the life-
time risks for HF were estimated to be approximately 20%
at all index ages, has a more stringent definition of HF as
compared with other cohorts (28).
Nevertheless, hospital discharge data, which were used
by the cohorts in the present study, demonstrate an
increased number of hospitalizations for HF and rising
costs associated with these hospitalizations (1). Our use
of the primary hospital discharge diagnosis may even
underestimate admissions with associated HF diagnoses.
Unlike coronary artery disease and stroke, where individ-
uals might “escape” some of their lifetime risk at older
index ages (29), lifetime risks for developing new-onset
HF continue to remain as high as 40% at age 75 years,
despite greater competing risks and substantially shorter
remaining lifespan at such an age. If risk factors for HF
are not treated more aggressively in both whites and
blacks, HF incidence and costs will likely increase fur-
ther, particularly as the U.S. population ages.
30-Year Cumulative Risk for HF at Index Age byin th CHA St dy by BMI StrataTable 2 30-Year Cumulative Risk for HF at Indin the CHA Study by BMI Strata
BMI
Men
White B
25 kg/m2 9.1 (7.2–10.9) 12.8 (
25–29 kg/m2 11.8 (10.3–13.3) 6.0 (
30 kg/m2 19.3 (16.1–22.5) 21.3 (
Values are mean (95% confidence interval). The cumulative risk was ad
Abbreviations as in Table 1.
30-Year Cumulative Risk for HF at Index Age 45in CHA by BP StrataTable 3 30-Year Cumulative Risk for HF at Iin CHA by BP Strata
BP White
120/80 mm Hg 9.8 (5.6–13
121–139 SBP or 81–89 DBP, mm Hg 10.9 (9.1–12
140–159 SBP or 90–99 DBP, mm Hg 12.1 (10.3–1
160 mm Hg SBP or 100 mm Hg DBP
or treated hypertension
16.3 (13.5–1
Values are means (95% confidence intervals). The cumulative risk wa
years. *There was an insufficient number of events to provide a stable estim
Abbreviations as in Table 1.Study limitations. First, we evaluated cohorts that defined
HF differently, which likely affected lifetime risk estimates
across different populations. However, these cohorts defined
HF through hospital discharge coding, which represents a
clinically relevant entity. Second, different cohorts had
different entry criteria and different index ages, ranging from
45 to 65 years, which also limits our analysis of these
cohorts across a wider age range. Third, our analysis of
ARIC was limited to the public-release dataset, which likely
explains our lower estimates compared with the internal
dataset with a longer follow-up through 85 years (15).
However, our estimates through age 75 years were similar to
those recently reported. Fourth, data were collected from
participants in different age ranges at different time points,
which could lead to birth cohort effects. The differences in
lifetime risks for HF between CHA and ARIC may be
partially explained by the increased prevalence of obesity
that occurred from 1967 to 1973 (CHA enrollment) to
1987 to 1989 (ARIC enrollment). Conversely, because
CHA HF events were collected through Medicare dis-
charge data, HF events that occurred before age 65 years or
the onset of hemodialysis or disability would have been
missed, leading to an underestimation of lifetime risks. The
prevalence of HF is 2% in U.S. adults ages 60 years (1),
suggesting that few incident cases would have been missed,
but data from ARIC indicate that more cases would be
missed among black men than other sex–race groups.
Similar trends between white and black participants at
younger ages as seen in ARIC also suggest that these
lifetime risk estimates are likely stable.
Race Groupge by Sex–Race Group
Women
White Black
.1) 7.7 (6.3–9.0) 4.4 (0.2–8.6)
.7) 11.5 (9.1–13.9) 11.4 (4.0–18.8)
.4) 16.6 (12.0–21.2) 21.8 (7.5–36.1)
for risk of death at index age 45 years; the follow-up age was 75 years.
ex–Race GroupAge 45 by Sex–Race Group
n Women
Black White Black
—* 9.9 (6.9–12.8) 6.9 (0–16.1)
7.5 (1.2–13.8) 8.6 (7.0–10.4) 7.9 (1.3–14.5)
13.9 (5.9–22.0) 9.2 (7.0–11.4) 6.7 (0–14.0)
12.7 (3.2–22.2) 13.3 (9.7–16.9) 16.0 (6.4–25.5)
ted for risk of death at index age 45 years; the follow-up age was 75Sex–ex A
lack
4.5–21
1.4–10
7.3–35by Sndex
Me
.9)
.7)
4.0)
9.2)
s adjus
ate.
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Lifetime Risk for Heart Failure by Sex and Race April 9, 2013:1510–7Conclusions
Lifetime risks for HF are very high for both black and
white men and women, underscoring the importance of
population-wide preventive efforts to curb the growing
burden of HF. These data should help clinicians, re-
searchers, and policymakers to more clearly understand
how great of a problem HF currently is and will continue
to be unless preventive measures are broadly imple-
mented.
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Index age 45 yrs 14.2 (12.4–16.0) —
Index age 55 yrs 13.9 (12.1–15.7) —
CHS
Index age 65 yrs 5.5 (3.2–7.8) 16.1 (13.4–18.7) 26.4
Index age 75 yrs — 13.1 (11.0–15.2) 26.0dedication in collecting the underlying data, and espe-
cially the study participants, whose dedication and com-
mitment have formed the basis of profound observations
regarding health and disease that have contributed to
improved health, longevity, and quality of life for millions
of persons.
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age of 45 years by sex–race group in the CHA (Chicago Heart Association Detec-
k estimate and unadjusted cumulative incidence (Kaplan-Meier estimate) is an
Ages by Sex/Race Groupsen Follow-Up Ages by Sex/Race Groups
Men
Black
75 85 95
27.3) 8.6 (6.2–10.9) 15.8 (12.2–19.4) 18.6* (14.4–22.9)
25.9) 7.7 (4.3–11.0) 15.4 (10.9–19.9) 18.1* (13.1–23.0)
15.9 (12.6–19.1) — —
16.1 (12.7–19.6) — —
29.7) 8.0 (3.1–12.8) 17.6 (11.5–23.7 22.1* (15.0–29.2)
29.3) — 14.2 (8.5–19.9) 20.7* (13.1–28.3)
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APPENDIX
For expanded information on estimating lifetime risk of HF,
Black
75 85 95
8.3 (5.7–10.9) 20.0 (15.1–24.9) 22.7* (16.7–28.6)
6.7 (2.7–10.7) 19.3 (12.8–25.7) 22.0* (14.7–29.2)
19.9 (16.4–23.4) — —
20.1 (16.5–23.8) — —
8.9 (4.6–13.1) 20.3 (15.1–25.4) 36.3 (28.8–43.8)
— 12.5 (8.4–16.6) 30.5 (22.7–38.4)
d antecedent myocardial infarction. *Limited to 90-year follow-up.omenplease see the online version of this paper.
